Evidence map›Paper›PMID 27251178›Full record

ArticleCancer science2016

Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer.

Yaxiong Cai, Jinxia Zhang, Xuejun Lao, Haowu Jiang, Yunfei Yu, Yanrui Deng, Jiangchuan Zhong, Yiye Liang, Likuan Xiong, Ning Deng

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Correction.Cancer science · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Knockout ofFrontiers in oncology · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yaxiong CaiGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.ORCID http://orcid.org/0000-0003-1058-6546
Jinxia ZhangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.
Xuejun LaoDepartment of Gastrointestinal Surgery, the First Clinical School in Jinan University, Guangzhou, China.
Haowu JiangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.
Yunfei YuGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.
Yanrui DengGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.
Jiangchuan ZhongGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.
Yiye LiangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.
Likuan XiongShenzhen Key Laboratory of Birth Defects in Baoan Maternal and Child Health Care Affiliated Hospital in Jinan University, Shenzhen, China.
Ning DengGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute in Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor-2 (FGF-2) is one of the most important angiogenic factors to promote tumor growth, progression and metastasis. Neutralizing antibodies against FGF-2 may suppress the growth of tumor cells by blocking the FGF-2 signaling pathway. In this study, a disulfide-stabilized diabody (ds-Diabody) that specifically targets FGF-2 was designed. Compared to its parent antibody, the introduction of disulphide bonds in the diabody could significantly increase the stability of ds-Diabody and maintain its antigen binding activity. The ds-Diabody against FGF-2 could effectively inhibit the tube formation and migration of vascular endothelial cells and block the proliferation and invasion of human breast cancer cells. In the mouse model of breast cancer xenograft tumors, the ds-Diabody against FGF-2 could significantly inhibit the growth of tumor cells. Moreover, the densities of microvessels stained with CD31 and lymphatic vessels stained with LYVE1 in tumors showed a significant decrease following treatment with the ds-Diabody against FGF-2. Our data indicated that the ds-Diabody against FGF-2 could inhibit tumor angiogenesis, lymphangiogenesis and tumor growth.

Indexed as

Protein MultimerizationAnimalsBALB 3T3 CellsBreast NeoplasmsCapillariesCell MovementCell ProliferationDisulfidesFemaleFibroblast Growth Factor 2HumansHuman Umbilical Vein Endothelial CellsImmunoglobulinsLymphangiogenesisMCF-7 CellsMiceDisulfidesFibroblast Growth Factor 2ImmunoglobulinsBreast cancerds-DiabodyFGF-2Pichia pastoristumor angiogenesis

Identifiers

PMID27251178
PMCPMC4982589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.